A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets

Firm Highlights LAI Olanzapine, As Trial Results Come Nine Months Ahead Of Schedule

 
• By David Wallace
  
Finger pushing innovation button
Another of Teva’s innovative assets has delivered results • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin